MedTrace Logo

The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow

NCT01468285 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-10-26

No results posted yet for this study

Summary

Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.

Conditions

  • Gait or Balance Disorder Problems

Interventions

DRUG

betahistine dihydrochloride

betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment

OTHER

placebo

placebo tablets b.i.d., six weeks treatment

Sponsors & Collaborators

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Dmitri Kazei, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468285 on ClinicalTrials.gov